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FK506 binding protein 51 (FKBP51, also called FKBP5) belongs to a family of immunophilins, FK506 binding proteins (FKBPs).
Members of this family are targets for drugs such as rapamycin and cyclosporine. Although FKBP5 shares characteristics with other
FKBPs, it also has unique features, especially its role in the regulation of multiple signalling pathways and in tumourigenesis and
chemoresistance. In this review, we will focus on the recently discovered role of FKBP5 in cancer aetiology and response to
antineoplastic therapy.
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FK506 binding protein 51 (FKBP51, also called FKBP5) is a
51-kDa FK506 binding protein that is a member of a family of
immunophilins, FK506 binding proteins (FKBPs). Members of
this family contain both FKBP domain(s) and tetratricopeptide
repeat (TPR) domain(s) (Kang et al, 2008). The FKBP domain
contains peptidylprolyl isomerase (PPIase) activity that catalyses
the cis–trans conversion of peptidylprolyl bonds, a reaction that is
important for protein folding (Fruman et al, 1994). The TPR
domains at the C terminus are involved in protein–protein
interactions (Scheufler et al, 2000). In general, TPR domains are
all-helical structures consisting of 2–16 units of a consensus 34-aa
motif. The domain is found in more than 800 different proteins
from bacteria and humans. The first described and most well-
known FKBP family member is FKBP12, a small protein with a
single FKBP domain and a molecular size of 12kDa. FK506 binding
protein 12 is a major binding partner for FK506 and rapamycin
(Siekierka et al, 1989). Additional members of this family have
been identified on the basis of their ability to bind FK506,
including FKBP13, FKBP25, FKBP38, FKBP52, and FKBP51
(named to reflect their molecular weights), all of which contain
the FKBP domain that is responsible for drug ligand binding and
PPIase activity (Kang et al, 2008).
Human FKBP5 was first cloned from a HeLa cell cDNA library
in 1995 (Baughman et al, 1995). It mediates FK506 inhibition
of calcineurin in vitro and is highly expressed in murine
T lymphocytes (Baughman et al, 1997). FK506 binding protein 5
contains two consecutive FKBP domains and a three-unit repeat
of the TPR domain (Figure 1). The first FKBP domain (FK1) of
FKBP5 shares 48% sequence identity to the FK domain of FKBP12
and has measurable PPIase activity, with a binding pocket for
FK506 and rapamycin (Sinars et al, 2003). FK2 is also structurally
similar to the FKBP domain of FKBP12, despite having only 26%
sequence identity. However, FK2 lacks measurable PPIase activity.
Presumably, FK2 resulted from an FK domain duplication event,
but subsequently lost its PPIase activity, while it appeared to have
gained protein interaction ability (Sinars et al, 2003). The FKBP5
structure study provides important initial insights into the relative
orientations of the FK1, FK2, and TPR domains that are important
for protein interaction and/or drug ligand binding (Sinars et al,
2003).
One of the major functions of FKBP5 is its involvement in the
modulation of steroid receptor function, including progesterone,
androgen and glucocorticoid receptors (GR), by forming a
complex with the heat shock proteins Hsp90/Hsp70. Both FKBP5
and its family member FKBP4 (also called FKBP52) are involved in
steroid receptor signalling, and their interchange served as the
earliest known event in steroid receptor activation. Davies et al
(2002) have used both in vitro and in vivo models to show the
hormone-induced loss of FKBP5 and gain of FKBP4, providing
evidence that the hormone-binding event causes an interchange of
FKBP5 and FKBP4 immunophilins within the GR heterocomplex.
The complex then dissociates, allowing the binding of GR to
DNA-binding motifs in its target genes to regulate gene transcrip-
tion (Figure 2A). Therefore, FKBP5 has been identified as a
sensitive biomarker of corticosteroid responsiveness in vivo
(Table 1) (Sinars et al, 2003; Rees-Unwin et al, 2007). In addition
to a role in tumourigenesis (see below), numerous studies have
also indicated that FKBP5 may have a role in psychiatric diseases
such as depression and in response to the treatment of depression
through modulation of hormone receptors (Schosser and Kasper,
2009). FK506 binding protein 5 and Hsp90 are also important for
the clearance of tau, a microtubule-associated protein that
accumulates in a group of neurodegenerative disorders such as
Alzheimer’s disease (Jinwal et al, 2010).
Of equal or greater interest than these effects on steroid
hormone signalling are recent studies that have indicated that
FKBP5 could also be a biomarker for tumourigenesis and chemo-
resistance. Roles in those processes extend beyond its functions
as a co-chaperone and a PPIase. Subsequent paragraphs will focus
on the discovery of the role of FKBP5 in cancer aetiology and
chemoresistance.
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Human FKBP5 is highly expressed in multiple tissues, including
kidney, skeletal muscle, liver, placenta, heart, and peripheral
blood. However, its expression level is much lower in the pancreas,
spleen, and stomach (Baughman et al, 1997). Although initial
studies found no detectable FKBP5 in the brain, colon, or lung,
subsequent studies have shown expression of FKBP5 in human
brain tissues (Nair et al, 1997) and colon tissues (Mukaide et al,
2008). FK506 binding protein 5 expression can be induced through
the activation of progesterone receptor, androgen receptor (AR),
and GR (Ratajczak et al, 2003). Hormone response elements in the
introns of FKBP5 regulate the induction of expression by
glucocorticoids, progesterone, and androgens. For example, Febbo
et al (2005) had identified FKBP5 as an androgen-inducible gene,
and demonstrated a physical interaction between FKBP5 and AR.
Recent studies have identified a long-range activation of FKBP5
transcription in prostate cancer cells by the AR via distal intronic
enhancers (Makkonen et al, 2009). The FKBP5 locus harbours
13 in silico-predicted androgen response elements (AREs), most of
which are located downstream from the transcription start site and
are capable of binding AR in vitro. These results indicated that
very distal AREs can act as robust enhancers, highlighting the
potential importance of the long-range regulation of FKBP5
expression by the AR (Makkonen et al, 2009). FK506 binding
protein 5 expression can also be induced by the GR in human lung
cancer A549 cells, where FKBP5 mRNA are accumulated in
response to dexamethasone exposure (Paakinaho et al, 2010).
A major intronic enhancer within the FKBP5 locus was identified
to bind to GR. There were also GREs identified in the proximal
promoter of FKBP5. The GR is capable of activating FKBP5
transcription and also evoking changes in chromatin structure
(Paakinaho et al, 2010). FK506 binding protein 5 can also function
within an auto-regulatory negative feedback loop to modulate
its own expression. Exogenous FKBP5 expression was able to
downregulate the transcription of genomic FKBP5 in the presence
of dexamethasone through this auto-regulation process (Park et al,
2007).
Both overexpression and downregulation of FKBP5 have been
observed in human cancers. According to the Oncomine, FKBP5 is
overexpressed in brain cancers, prostate cancer, lymphoma, head
and neck cancer, and melanoma. On the other hand, FKBP5
has also been shown to be downregulated in pancreatic cancer
(Pei et al, 2009), melanoma, colon cancer, and testicular cancer.
Gene expression data for those studies are available through the
Oncomine, and studies describing these observations are also
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Figure 1 Structure of FKBP5 with its major domains that are critical for
its function as well as with the list of its interactive proteins by domain.
AKT¼a serine/threonine protein kinase, also called PKB; AR¼androgen
receptor; FK¼FKBP-type domain; GR¼glucocorticoid receptor; Hsp90¼
heat shock protein 90; IKKa¼IkB kinase a subunit; PHLPP¼PH domain
and leucine-rich repeat protein phosphatases; PR¼progesterone receptor;
TPR¼tetratricopeptide repeat.
Ser473 P
GR
Hsp90
GR
FKBP5
GR
Hsp90
FKBP4
FKBP5
IKK
IB
A
Dexomethasone
B
Radiation/doxorubicin
C
Chemotherapy
Survival Apoptosis
FKBP5
Apoptosis
Nucleus
AKT off AKT on
PHLPP
Thr308 P
FKBP5
mTORC1
S6K1
S6
P PDK1
P
PI3K
PIP3
PP2A
mTORC2
Gene activation Gene activation
Cellular membrane
NF-B on NF-B off
NF-B on
Figure 2 Schematic model of FKBP5 functions involved in several different signalling pathways, including glucocorticoid receptor (GR) signalling
pathways (A), as well as NF-kB( B) and AKT–PHLPP (C) pathways. (A) In the absence of dexamethasone, FKBP5 is the primary immunophilin of the
FKBP–Hsp90–GR complex in an inactive stable state. Upon dexamethasone binding, FKBP5 is displaced by FKBP4, and the complex can enter the nucleus.
The complex then dissociates, allowing binding of GR to DNA-binding motifs of target genes, leading to apoptosis. (B) In the presence of doxorubicin or
damage from radiation, FKBP5 might involve in the control of IKKa activity, which can induce IkBa degradation via its phosphorylation, nuclear translocation,
and activation of NF-kB, and the expression of its target genes, consequently triggering cell apoptosis. (C) FK506 binding protein 5 interacts with PHLPP and
AKT, acting as a scaffolding protein that promotes the interaction between AKT and PHLPP, thereby enhancing the dephosphorylation of AKT and
inactivating AKT, which results in the blockade of AKT signalling for cell survival and leads to cell apoptosis or death.
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its expression pattern, FKBP5 has been shown to either promote
or suppress tumour growth through its regulation of different
signalling pathways in a specific tissue environment.
ROLE OF FKBP5 IN TUMOURIGENESIS AND
RESPONSE TO ANTINEOPLASTIC THERAPY
FK506 binding protein 5 has been shown to be involved in several
different signalling pathways, including steroid receptor signalling
pathways, NF-kB, and AKT (a serine/threonine protein kinase, also
called PKB)–PHLPP (leucine-rich repeat protein phosphatase)
pathways, all of which have important roles in tumourigenesis and
response to antineoplastic chemotherapy (Figure 2 and Table 1).
FK506 binding protein 5 is a key regulatory component of
the androgen–receptor complex
Although FKBP5 knockout mice show normal androgen signalling
(Yong et al, 2007), it has been linked to AR signalling and prostate
cancer. As discussed above, FKBP5 itself is a target gene of AR.
FK506 binding protein 5 can form a complex with AR to enhance
AR transcriptional activity in prostate cancer (Febbo et al, 2005).
Recently, Ni et al (2010) showed that FKBP5 stimulates the
recruitment of cochaperone p23 to the ATP-bound form of Hsp90,
forming an FKBP5–Hsp90–p23 superchaperone complex, which
stimulates androgen-dependent transcription activation and cell
growth. Therefore, FKBP5 might serve as a novel drug target to
help disrupt AR-mediated signalling in prostate cancer.
FK506 binding protein 5 regulates the NF-jB pathway
Bouwmeester et al (2004) first identified a physical interaction
between FKBP5 and nuclear factor IkB kinase a subunit (IKKa)
during a proteomics study. In that study, FKBP5 was copurified
with IKKa as well as IKKe, TGF beta activated kinase 1, and
MAP kinase/ERK kinase kinase 1 (Bouwmeester et al, 2004). The
interaction with IKKa was confirmed by co-immunoprecipitation.
These results indicated that FKBP5 might have a role in NF-kB
signalling.
Several studies by Romano et al have demonstrated that the
downregulation of FKBP5 can sensitise cells to irradiation and
anthracyclines through the regulation of NF-kB (Avellino et al,
2005). They showed that treatment of melanoma or acute
lymphoblastic leukaemia cell lines with anthracycline would
induce NF-kB activity. However, treatment with rapamycin signi-
ficantly sensitised the cells to anthracycline by inhibition of the
NF-kB activity. This effect was associated with FKBP5 activity,
as downregulation of FKBP5 increased the rapamycin inhibition of
NF-kB activity, and, in turn, increased apoptosis (Avellino et al,
2005). In addition, the same group also found that higher
expression of FKBP5 might influence radioresistance through the
activation of NF-kB in melanoma cells (Romano et al, 2010). They
also found that FKBP5 was overexpressed in melanoma samples
compared with normal skin tissue, and pretreatment of mice
xenograft tumours with FKBP5-siRNA provoked massive apopto-
sis after irradiation (Romano et al, 2010). These experiments
provided evidence that, both in vitro and in vivo, FKBP5 might be
a promising target for radiosensitising agents against malignant
melanoma.
FK506 binding protein 5 is a negative regulator of AKT
activation in tumourigenesis and chemoresistance
Regulation of NF-kB by FKBP5 emphasised the potential
importance of FKBP5 in tumourigenesis and response to therapy.
However, it was not until very recently that another important
function of FKBP5 was identified. Studies from our laboratory first
demonstrated, through the use of genome-wide screening, that
levels of FKBP5 were associated with response to two cytidine
analogues, gemcitabine and cytosine arabinoside (AraC) (Li et al,
2008). Higher levels of expression of FKBP5 were associated with
sensitivity and lower levels of expression were associated with
resistance to gemcitabine and AraC. Furthermore, downregulation
of FKBP5 desensitised pancreatic and breast cancer cell lines to
several different classes of chemotherapeutic agents, including not
only cytidine analogues but also taxanes, ironotecan, and etopo-
side (Li et al, 2008; Pei et al, 2009). In this case, the actions of
FKBP5 on NF-kB activation or hormone induction could not
explain the increased chemoresistance in cells with decreased
FKBP5 expression, suggesting the existence of other mechanisms
by which FKBP5 regulates cell survival.
We recently identified FKBP5 as a negative regulator of AKT
(Pei et al, 2009). Full activation of AKT requires phosphorylation
at Thr308 within the activation loop of the kinase domain and
Ser473 at a hydrophobic motif just C-terminal to the kinase
domain. Thr308 is phosphorylated by pyruvate dehydrogenase
kinase isozyme 1, mitochondrial (Alessi et al, 1997), while Ser473
is phosphorylated by mTOR complex 2 (Sarbassov et al, 2005).
AKT activity is also negatively regulated by lipid or protein
phosphatases. Two protein phosphatases have been shown to
dephosphorylate AKT and negatively regulate AKT acivity. Protein
phosphatase 2 (PP2, also known as PP2A) holoenzymes dephos-
phorylate Ser308 (Padmanabhan et al, 2009), while PH domain and
leucine-rich repeat protein phosphatase 1 and 2 (PHLPP1 and 2)
Table 1 Table of relationship between FKBP5 levels in cancer and drug activity of antineoplastic agents
Antineoplastic
agent
Signalling pathway
involved
Type of
cancer
Change in FKBP51
expression
Alteration of drug susceptibility
antineoplastic agent Reference
FK506, rapamycin PR, GR Breast cancer Upregulated Resistance Le Bihan, Marsaud et al (1998)
FK506 AR Prostate cancer Upregulated Resistance Ni et al (2010)
Dexamethasone GR Myeloma Upregulated Resistance Rees-Unwin et al (2007)
Rapamycin NF-kB ALL, melanoma Upregulated Resistance Romano, Avellino et al (2004);
Avellino et al (2005)
Irradiation NF-kB Melanoma Upregulated Resistance Romano et al (2010)
Gemcitabine AKT Downregulated
AraC AKT Downregulated
Epitoside AKT Pancreatic cancer,
breast cancer
Downregulated Resistance Li et al (2008); Pei et al (2009)
Texane AKT Downregulated
Abbreviations: AKT¼a serine/threonine protein kinase, also called protein kinase B; AR¼androgen receptor; FKBP5¼ FK506 binding protein 5; GR¼glucocorticoid receptor;
NF-kB¼nuclear factor-kB; PR¼progesterone receptor.
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the balance between kinases and phosphatases determines AKT
activity. We found that FKBP5 functions as a scaffolding protein
that enhances the PHLPP–AKT interaction and facilitates PHLPP-
mediated dephosphorylation of AKT-Ser473. Downregulation of
FKBP5 results in decreased PHLPP–AKT interaction and in-
creased AKT phosphorylation. Therefore, FKBP5 might also
function as a tumour suppressor in the AKT signalling pathway,
similar to phosphatase and tensin homologue (PTEN). Indeed, we
found that FKBP5 levels were low or absent in pancreatic cancer
cell lines and tissue samples from patients with pancreatic cancer,
correlating with increased AKT Ser473 phosphorylation. We also
observed downregulation of FKBP5 in breast cancer cell lines. High
levels of FKBP5 led to decreased AKT phosphorylation and
increased chemosensitivity, whereas low levels of FKBP5 resulted
in increased AKT phosphorylation and decreased chemosensiti-
vity. These observations make FKBP5 a potentially important
biomarker for sensitivity to chemotherapy, and variation in FKBP5
levels might determine patient responses to chemotherapy
(Figure 2C and Table 1) (Pei et al, 2009). In addition,
determination of levels of FKBP5 might provide insights that
could help to select patients for different combination therapies
with inhibitors targeting the AKT pathway (Pei et al, 2009).
CONCLUSIONS
In summary, FKBP5 has altered expression levels in many
different tumours. Through its influence on steroid receptor
maturation, as well as NF-kB and AKT signalling pathways, FKBP5
plays an important role in tumourigenesis and response to anti-
neoplastic therapy (Figure 2 and Table 1). All of these observations
raise the possibility that FKBP5 might be a biomarker for
chemoradiosensitivity. On the basis of studies using lymphoblas-
toid cell lines from 300 individuals, we have observed large vari-
ations in FKBP5 expression that correlate with cellular sensitivity
to gemcitabine and AraC (Li et al, 2008). Future studies will be
needed to confirm the role of FKBP5 in predicting chemo-
sensitivity in clinical samples. In addition, it would be important to
investigate factors that are responsible for variation in FKBP5
expression in individuals. Common single-nucleotide polymor-
phisms (SNPs) in the FKBP5 gene might contribute to variation
in FKBP5 protein expression. Therefore, genotyping these SNPs
and determining how they affect FKBP5 expression and, thus, drug
sensitivity or tumourigenesis might be important next steps for this
line of investigation. Additionally, the role of FKBP5 in tumouri-
genesis remains controversial. Whether FKBP5 functions as an
oncogene or a tumour suppressor might depend on the tissue type
and differences among pathways expressed in those tumours. For
example, FKBP5 is found to be downregulated in pancreatic tumour
tissue, while it is overexpressed in melanoma. These discrepancies
need to be further clarified in the future using animal models.
Because of the role of FKBP5 in the regulation of multiple
important biological pathways as discussed in this review,
variation in FKBP5 could be of significance in many diseases
beyond cancer, and in diseases such as diabetes (Tian, 2005). All
of these possibilities will need to be investigated. Future studies
will also be required to address questions such as how FKBP5
is regulated, and whether there are other pathways in which
FKBP5 might be involved.
In summary, FKBP5 has multiple roles in the regulation of
a variety of signalling pathways. Therefore, understanding the
mechanisms underlying its regulation and its role in the
development of cancer and in response to anti-neoplastic therapy
could help make it possible to better individualise the treatment of
human disease.
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